Accepted for/Published in: JMIR Research Protocols
Date Submitted: Apr 12, 2022
Open Peer Review Period: Apr 12, 2022 - Jun 7, 2022
Date Accepted: Mar 5, 2023
(closed for review but you can still tweet)
Warning: This is an author submission that is not peer-reviewed or edited. Preprints - unless they show as "accepted" - should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.
Off-label use of bevacizumab in age-related macular degeneration: protocol for a systematic review and meta-analysis
ABSTRACT
Background:
Age-related macular degeneration (AMD) is recognized as the leading cause of vision loss in elderly people. Taking into account the phenomenon of aging worldwide, the prevalence of AMD is expected to increase gradually in the future. AMD can be divided into early, intermediate and late stages, where early and intermediate are mainly asymptomatic and, late-stage can be classified in non-vascular AMD and vascular AMD. Current pharmacological treatment in vascular AMD includes the administration of anti-VEGF agents, such as ranibizumab, pegaptanib, and aflibercept. Additionally, it has been reported that the off-label use of bevacizumab, through intravitreal administrations, demonstrates to be effective along with a lower cost in comparison to other agents used, which makes it a new possible pharmacological approach.
Objective:
This review aims to evaluate the efficacy, safety, and efficiency of the use of bevacizumab in the treatment of neovascular AMD
Methods:
To identify and select relevant articles present in current literature, it will be developed a highly sensitive search strategy. To develop this search, it will be used MEDLINE via the Pubmed platform. It will be only considered randomized controlled clinical trials, where it is compared the use of bevacizumab with another pharmacological agent, such as ranibizumab, or even a placebo, in patients aged 50 years and older, diagnosed with vascular AMD.
Results:
This project has no funding and it has been done by a multidisciplinary research team of pharmacologists and orthoptists. The study was initiated in May 2021 with the lineation of the protocol, now the data are been extracted and analyzed, and it is expected to be released by the end of 2022.
Conclusions:
This review will provide a synthesis of the current information and underlying evidence, about the influence of the off-label use of bevacizumab in this disease. Altogether, it will allow having a clearer vision of a new possible accepted pharmacological approach for the treatment of vascular AMD. Clinical Trial: The protocol for this review was registered in the International Prospective Register of Systematic Reviews (PROSPERO) with the code CRD42021244931.
Citation
Request queued. Please wait while the file is being generated. It may take some time.
Copyright
© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.